Who
Dennis A. Ausiello
Director
Company insider
Files Form 4 as: Director, Seres Therapeutics; Director, Rani Therapeutics Holdings; Director, Alnylam Pharmaceuticals; Director, Pfizer.
In numbers
- Trades disclosed
- 130
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $33.5M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 1 Dec 2006
- Last trade
- 8 Jul 2026
- Last filed
- 10 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jul 2026filed 10 Jul 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,508 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,508 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | RANI Rani Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —123,600 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | RANI Rani Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —123,600 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —671 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,441 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,441 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —671 at $0.00 | filing |
| 14 Aug 2025filed 15 Aug 2025 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,000 at $0.00 | filing |
| 14 Aug 2025filed 15 Aug 2025 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,153 at $0.00 | filing |
| 14 Aug 2025filed 15 Aug 2025 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,581 at $0.00 | filing |
| 14 Aug 2025filed 15 Aug 2025 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,228 at $0.00 | filing |
| 14 Aug 2025filed 15 Aug 2025 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,032 at $0.00 | filing |
| 14 Aug 2025filed 15 Aug 2025 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,454 at $0.00 | filing |
| 14 Aug 2025filed 15 Aug 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $648K9,000 at $72.01 | filing |
| 14 Aug 2025filed 15 Aug 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $661K5,153 at $128.31 | filing |
| 14 Aug 2025filed 15 Aug 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $682K4,581 at $148.77 | filing |
| 14 Aug 2025filed 15 Aug 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $791K5,228 at $151.22 | filing |
News
Alnylam Pharmaceuticals (NASDAQ:ALNY) versus Oncocyte (NASDAQ:IMDX) Head to Head ComparisonALNY · dailypolitical.com · 21 Oct 2026Alnylam Pharmaceuticals (NASDAQ:ALNY) and TScan Therapeutics (NASDAQ:TCRX) Critical SurveyALNY · themarketsdaily.com · 20 Oct 2026Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Reduction from Wells Fargo & CompanyALNY · tickerreport.com · 17 Oct 2026
0 headlines in the last 90 days name Dennis A. Ausiello; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.